title: New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.
abstract: Reduction of anticancer prodrugs such as ctc-[PtCl(2)(CH(3)CO(2))(2)(NH(3))(Am)] can yield three products in addition to the expected cis-[PtCl(2)(NH(3))(Am)]. A possible explanation is that reduction proceeds by several pathways where in addition to the loss of two axial ligands, one axial (acetato) and one equatorial (chlorido) ligand, or two equatorial ligands are eliminated.
authors.affiliation: Department of Medicinal Chemistry and Natural Products, Institute of Drug Research, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
authors.forename: Alina
authors.initials: A
authors.lastname: Nemirovski
authors.forename: Inbal
authors.initials: I
authors.lastname: Vinograd
authors.forename: Khuloud
authors.initials: K
authors.lastname: Takrouri
authors.forename: Ana
authors.initials: A
authors.lastname: Mijovilovich
authors.forename: Annette
authors.initials: A
authors.lastname: Rompel
authors.forename: Dan
authors.initials: D
authors.lastname: Gibson
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D009944:Organoplatinum Compounds / Q000737:chemistry*; D010084:Oxidation-Reduction; D011355:Prodrugs / Q000737:chemistry* / Q000494:pharmacology; D056928:X-Ray Absorption Spectroscopy
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011355:Prodrugs